Akebia Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 167
- Market Cap
- $319.6M
- Website
- http://www.akebia.com
- Introduction
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
- Conditions
- Drug Interaction Potentiation
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 62
- Registration Number
- NCT03801759
- Locations
- 🇨🇦
inVentiv Health Clinique Inc., Québec City, Quebec, Canada
Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
- Conditions
- AnemiaDialysis-dependent Chronic Kidney Disease
- Interventions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 175
- Registration Number
- NCT03799627
- Locations
- 🇺🇸
Research Site, Wauwatosa, Wisconsin, United States
🇺🇸Research Site #1, Minneapolis, Minnesota, United States
🇺🇸Research Site #2, Minneapolis, Minnesota, United States
A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT03799848
- Locations
- 🇺🇸
Prism Clinical Research, Saint Paul, Minnesota, United States
🇺🇸American Research Corporation at the University of Texas Liver Institute, San Antonio, Texas, United States
Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat
- Conditions
- Drug Interaction PotentiationPharmacokinetics
- Interventions
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT03789032
- Locations
- 🇨🇦
inVentiv Health Clinique Inc., Québec City, Quebec, Canada
A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 54
- Registration Number
- NCT03657290
- Locations
- 🇺🇸
Paraxel International, Baltimore, Maryland, United States
A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT03639155
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 196
- Registration Number
- NCT03254485
- Locations
- 🇺🇸
Arizona Arrhythmia Research Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- AnemiaDialysis-Dependent Chronic Kidney Disease
- Interventions
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Akebia Therapeutics
- Registration Number
- NCT03242967
- Locations
- 🇺🇸
Research Site, Northridge, California, United States
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
- Conditions
- Type 2 Diabetes Mellitus With Diabetic Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 156
- Registration Number
- NCT03217591
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸California Institute of Renal Research, La Mesa, California, United States
🇺🇸St. Joseph Heritage Healthcare (St. Jude Hospital DBA), Fullerton, California, United States
Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents
- Conditions
- Dialysis-Dependent Chronic Kidney DiseaseAnemia
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT03140722
- Locations
- 🇺🇸
Research Site, Norfolk, Virginia, United States